Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Atara Biotherapeutics (ATRA) Research & Development (2022 - 2025)

Atara Biotherapeutics' Research & Development history spans 4 years, with the latest figure at -$223000.0 for Q4 2025.

  • For Q4 2025, Research & Development fell 100.78% year-over-year to -$223000.0; the TTM value through Dec 2025 reached $37.4 million, down 75.28%, while the annual FY2025 figure was $37.4 million, 75.28% down from the prior year.
  • Research & Development reached -$223000.0 in Q4 2025 per ATRA's latest filing, down from $2.9 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $75.0 million in Q1 2022 to a low of -$223000.0 in Q4 2025.
  • Average Research & Development over 4 years is $42.9 million, with a median of $47.6 million recorded in 2023.
  • Peak YoY movement for Research & Development: dropped 13.49% in 2023, then plummeted 100.78% in 2025.
  • A 4-year view of Research & Development shows it stood at $62.5 million in 2022, then fell by 20.66% to $49.6 million in 2023, then tumbled by 42.09% to $28.7 million in 2024, then tumbled by 100.78% to -$223000.0 in 2025.
  • Per Business Quant, the three most recent readings for ATRA's Research & Development are -$223000.0 (Q4 2025), $2.9 million (Q3 2025), and $7.3 million (Q2 2025).